A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
September 10, 2026
A Phase 1a/1b, Open-label, Dose-escalation and Dose-expansion Study of UBX-303061 in Relapsed/Refractory B-Cell Malignancies